According to the European Medicines Agency (EMA) recommendations, durvalumab use was approved in Italy in September 2018, restricted to patients with a PD-L1 tumor proportion score (TPS) >1%, following a post-hoc analysis showing that patients with tumors expressing PD-L1 below 1% lacked any survival advantage over control. This evidence concerns the gene CD274 and neoplasm.